Sundial SNDL stock analysis and what to expect next with SNDL stock

Alzheimer’s drug Leqembi gets full OK; Biotech’s H1 by the numbers; Bringing Leerink back; Against AI overhype; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit

July 9, 2023

Research sheds light on the causes of endometriosis-related pelvic pain

Pelvic pain in women with endometriosis is attributed to neuroinflammation. Researchers investigated biochemical mediators of endometriosis-associated pelvic pain to provide a foundation to identify new

August 3, 2023

Study finds increase in mental health spending for children, adolescents since the beginning of pandemic

Spending on mental health services for children and adolescents has risen by more than one-quarter since the beginning of the COVID-19 pandemic, continuing to rise

October 5, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.